Skip to main content

Teladoc Health Inc

For the period ended May 23, 2024. Filed Apr 9, 2024.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

May 23, 2024 · Filed Apr 9, 2024

TDOC$8.77-6.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Proxy summary

This summary contains highlights about Teladoc Health, Inc. (“Teladoc Health,” the “Company” or “we”) and its upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”). This summary does not contain all of the information that you should consider in advance of the meeting, and we encourage you to read the entire proxy statement carefully before voting.

2024 Annual meeting

WhenVirtual meetingRecord date
Thursday, May 23, 20242:00 p.m. EDTwww.virtualshareholdermeeting.com/TDOC2024March 28, 2024
Voting matters · Boardrecommendations · For more information,see page
1Election of eight director nomineesFOR each nominee10
2Advisory vote to approve executive compensation (Say-on-Pay)FOR27
3Advisory vote to approve the frequency of future advisory votes on the compensation of Teladoc Health’s named executive officers1 YEAR69
4Ratification of the selection of Ernst & Young LLP as independent auditors for 2024FOR70
2024 Proxy StatementTeladoc Health1

Proxy summary

2023 Performance and company highlights

Executing our 2023 priorities:

$2.6B$328M(1)$194M(1)
Revenue growth of 8%Adjusted EBITDA growth of 33%Free cash flow, up from $17M
$1.5B$1.1B1.2M
U.S. integrated care revenue, up 7%BetterHelp revenue, up 11%Chronic care program enrollment, up 14%

(1)For a full reconciliation of (i) net loss, the most directly comparable GAAP financial measure, to adjusted EBITDA and (ii) net cash provided by operating activities, the most directly comparable GAAP financial measure, to free cash flow, please see the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Consolidated Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

2Teladoc Health2024 Proxy Statement

Proxy summary

Human capital management and diversity, equity and inclusion

At Teladoc Health, we live our values as a company through policies, governance, and deliberate investment in operating responsibly and sustainably. We are committed to making a positive impact in society and, perhaps even more importantly, to encourage others of like mind and spirit to join us in this critical work.

To fulfill our mission, we are focused on building a great company that becomes a global destination for amazing talent who want to build their careers, develop their capabilities, and grow both professionally and personally. We design a range of programs and initiatives to:

nurture talent

encourage curiosity and innovation

make room for diverse voices and perspectives

increase engagement and connectiveness

mentor leaders for future roles

We build a range of total reward programs that support employees through fair, equitable, and competitive pay and benefits, and we invest in technology, tools and resources to transform and increase the quality of work.

We continue to look for ways to expand a range of programs and initiatives that are focused to attract, develop and retain our workforce—including a focused engagement through diversity, equity, and inclusion (“DEI”). We have enhanced our talent efforts in recent years to include:

Supporting Employees Through Our Products and ServicesTalent DevelopmentBusiness Resource Groups
We offer our employees full access to our diverse portfolio of whole-person health solutions, including:•free mental health resources•digital health devices•on-demand access to the employee assistance program for employees and their dependentsWe prioritize and invest in creating opportunities to help employees grow and build their careers, through training and development programs. These include:•online and self-paced courses•live in-class education•professional speaker series•peer-to-peer learning•certification programs•on-the-job training•executive talent and succession planning paired with an individualized development approachWe believe our business resource groups (“BRGs”), are a foundational element of the DEI ecosystem. Our seven BRGs include a focus on LGBTQ+, women, multicultural, military veterans, neurodiversity and differing physical and mental abilities, working parents and caregivers, and generational interests of employees who are engaged in four key pillars:•Building internal community/network•Advancing external community•Supporting business impact•Enhancing professional development
Community Impact
We embrace the opportunity and the responsibility to have a meaningful impact in our global community, using our voice and our resources to help expand equitable access to care, and create a better future for families and our neighbors. We continue to work toward further mobilizing our workforce to give back to the communities where we live and work through new volunteer programs and corporate matching opportunities for giving.We set out to advance positive social change in our communities with a 2023 achievement of volunteering more than 13,000 hours around the globe. This was a monumental achievement that was consistent with our values, including those of respecting and taking care of people, doing what’s right, and succeeding together. For 2024, we have continued to challenge ourselves and set goals for volunteer hours to do good and give back to our communities.
2024 Proxy StatementTeladoc Health3

Proxy summary

Expanding the Voice of the EmployeeOpen Dialogue to Encourage Diverse Thinking and VoicesFocusing on Diversity Recruiting and Talent Acquisition
We strive to build a culture of inclusion which includes regularly soliciting employee feedback through our pulse engagement surveys, listening circles and seeking opportunities to advance employee feedback.We have invested in our employees and broadened our external speaker series, interactive expert discussions, and self-paced learning programs to expand knowledge and awareness of diversity and health topics.We continue to broaden our diversity hiring manager training resources for performance-based interviewing, which included a screening tool to promote gender-neutral job descriptions.We expanded our corporate and college/university partnerships to advance our pipeline of diverse talent.

Building stronger, healthier communities

We aim to do more than improve the healthcare experience. From our boots-on-the-ground efforts to our reform-on-the-Hill initiatives, we also strive to enhance the lives of the people and communities we serve.

In the aftermath of a natural disaster, urgent care and doctors’ offices can be slow to reopen due to power outages or damages. This year, we enabled free visits for communities recovering from natural disasters all across the U.S., helping families get access to necessary prescriptions and care. In addition, BetterHelp’s social good program enabled thousands of hours of free therapy for communities in need—from Ukraine to the Middle East.

In 2023, we completed disaster missions to support relief in eight states reeling from hurricanes and other natural events.

Wildfiresin Hawaii

Mudslidesin California

Tornadosin Arkansas, Mississippiand Tennessee

Hurricane Idaliain Florida, Georgia and South Carolina

4Teladoc Health2024 Proxy Statement

Proxy summary

Health equity

Our commitment to health equity is central to our mission of empowering all people everywhere to achieve their healthiest lives. We continue to make targeted investments to advance health equity by capturing and leveraging actionable data, designing for equity in our products and services, supporting the social drivers of health, and contributing to the industry's collective progress in this area via partnerships and collaboration.

As health equity increasingly becomes a regulatory and market differentiating reality for our Clients, Teladoc Health remains well positioned to meet the diverse needs, preferences, and circumstances of those whom we collectively serve. Our size, scale, and quality infrastructure enable us to continually assess and improve our services in order to deliver equitable access, experiences, and outcomes for all.

Corporate governance highlights

Corporate Governance Best Practices

Annual election of directors

2 of our director nominees are women

1 of our director nominees is ethnically/racially diverse

All of our director nominees are independent

Independent Board chair

Balance of new and experienced directors

No overboarding

Annual director self-evaluation and committee assessment to ensure Board effectiveness

Multiple members of our Audit Committee qualify as “audit committee financial experts”

All current directors attended at least 75% of 2023 meetings

Regular executive sessions of independent directors

Majority voting standard in uncontested elections

Stockholder ability to call special meetings

Proxy access (3/3/20/25)

Enterprise Risk Management program to oversee organizational risk

Code of Business Conduct and Ethics

Annual Say-on-Pay vote

Independent compensation consultant

Pay-for-performance philosophy

Stock ownership guidelines for directors and executives

No hedging or pledging of company stock

Clawback policy

Active stockholder engagement

Commitment to corporate social responsibility

2024 Proxy StatementTeladoc Health5

Proxy summary

Board of directors overview

Director nominees

Director nominee and principal occupation · Age · Director since · Independent · Current committee membership
AC · CC · NCGC · QCPSC · EC
J. Eric Evans(1)Chief Executive Officer, Surgery Partners472023
Sandra L. FenwickRetired Chief Executive Officer, Boston Children’s Hospital732020
Catherine A. Jacobson(2)Chief Executive Officer, Froedtert ThedaCare Health602020
Thomas G. McKinley(3)General Partner,Cardinal Partners722009
Kenneth H. PaulusRetired President and Chief Executive Officer, Prime Therapeutics642017
David L. ShedlarzRetired Vice Chairman, Executive Vice President and CFO, Pfizer752016
Mark Douglas Smith, M.D., MBAClinical Professor of Medicine, University of California at San Francisco; and a board-certified internist722018
David B. Snow, Jr. Chairman and Chief Executive Officer, Cedar Gate Technologies692014
Meetings in 2023Board - 1055740
Committee chairCommittee memberAAudit committee financial expert
ACAuditNCGCNominating & corporate governanceECExecutive
CCCompensationQCPSCQuality of care & patient safety

(1)Mr. Evans is expected to serve as Chair of the Compensation Committee and as a member of the Audit Committee and the Executive Committee following the Annual Meeting.

(2)Ms. Jacobson is also expected to serve as a member of the Quality of Care and Patient Safety Committee following the Annual Meeting.

(3)Mr. McKinley is expected to continue to serve as a member of the Compensation Committee and to serve as a member of the Audit Committee following the Annual Meeting. He is expected to leave the Executive Committee concurrently with Mr. Evan’s appointment as Chair of the Compensation Committee.

6Teladoc Health2024 Proxy Statement

Proxy summary

Board attributes

Our director nominees compose a well-balanced, diverse Board of Directors (the “Board”).

IndependenceTenure
100%Independent7yearsAverage tenure
AgeDiversity
67yearsAverage age38%Diverse
2024 Proxy StatementTeladoc Health7

Proxy summary

Board refreshment

Three of our independent director nominees have joined our Board since 2020, representing 38% of our director nominees.

20202023
Sandra L. FenwickCatherine A. JacobsonJ. Eric Evans

Key director skills and experience

This table summarizes the key skills, attributes and experiences of each of our director nominees that are most relevant to their board service. The fact that a specific area of focus or experience is not designated does not mean the director nominee does not possess that attribute or expertise.

Academics2/825%
Audit and financial reporting4/850%
Corporate governance7/888%
Executive leadership8/8100%
Finance and investment industry1/813%
Healthcare and medicine8/8100%
Human capital management8/8100%
Other public company board experience7/888%
Regulatory, government and compliance7/888%
Risk management8/8100%
Strategic planning and operations8/8100%
Technology and innovation4/850%
8Teladoc Health2024 Proxy Statement

Proxy summary

Executive compensation highlights

Our Compensation Committee has designed our executive compensation program in alignment with our key strategic priorities and commitment to aligning executive pay with corporate performance and stockholder interests. Accordingly, long-term incentives in the form of stock awards make up the significant majority of our named executive officers’ total target compensation such that their pay outcomes are directly linked to our stockholders’ experience.

Total 2023 target compensation mix

CEO

Average of other NEOs

Consideration of say-on-pay advisory vote

•While the most recent Say-on-Pay vote indicates significant stockholder support of the philosophy, strategy and objectives of our executive compensation programs, the Compensation Committee recognizes the relative year over year decline in support and intends to seek to further align executive compensation with stockholder interests.•Following the annual review of our executive compensation philosophy by our Compensation Committee, as well as our most recent Say-on-Pay results and engagement with stockholders, our overall approach to executive compensation will not change. However, we have adjusted our compensation program in response to stockholder feedback by further emphasizing long-term performance periods for performance-based restricted stock units and altering our 2024 equity grant practices to reduce our burn rate.•The Compensation Committee will continue to monitor stockholder feedback, including the results of the annual Say-on-Pay vote, in making future decisions affecting our compensation programs.SIGNIFICANT STOCKHOLDER APPROVAL OF SAY-ON-PAY OVER LAST 3 YEARS2021 – 87.2%2022 – 91.6%2023 – 81.9%
2024 Proxy StatementTeladoc Health9
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.